<aside> 🔮 We’re precision manufacturing human cells for therapy using AI-first biology*.***
</aside>
CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol.
We’re working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world.
Our mission is bold and ambitious and we have the best investors behind us from day 1. We’re backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We’re also supported by the founder/CEO of Abcam, which pioneered the antibody business.
What if we could cure diseases by replacing a patient’s unhealthy cells with newly generated healthy cells?
At CellVoyant we are pioneering novel platform technologies to manufacture stem-cell based cell therapies that are robust, controllable, efficient and safe.
Why does this matter? Today’s approach to stem cell differentiation is artisanal, slow and inefficient. The industry measures the start and end states of tissues, flying blind as to the real time dynamics of cell fate decisions, which results in suboptimal tissue manufacturing protocols at best. With hundreds of clinical trials ongoing and upcoming, we need a better way to deliver effective life-changing therapies to patients.
At CellVoyant, we’re combining large-scale cell culture and live cell imaging with data-driven computer vision to predict and optimise cell fate decisions in real-time. This approach allows us to uncover and control optimal routes for programming stem cells into any desired adult cell type.
The result is a closed-loop, data-driven Google Maps navigation system for precision cell engineering.
Ownership: Our biggest asset is our people. We believe in strong company ownership via equity for all employees.
Ingenuity: We fundamentally believe that “biology is living its AI moment”. You’ll have the opportunity to solve problems across cell biology, machine learning and engineering that do not have a textbook answer.
Creative freedom: We pride ourselves on being bold, ambitious and creative. We offer you the freedom to achieve our mission in the most effective way possible. We will dare you to question the status quo, challenge you to problem solve and empower you to succeed.
Collaboration: We thrive on collaboration to push the boundaries of our field. We value diverse perspectives and backgrounds, encourage creativity and open mindedness, and harness our differences to think outside of the box. Inclusion and empowerment are at the heart of our culture - creating impact together is what drives us.
We seamlessly merge lab-based experimental biology with computing. We run a hybrid working setup with a lab and separate office based in Bristol, UK. Our wet lab scientists are based out of Bristol and our computational team are both based in Bristol and remote. We run off-sites quarterly to bring everyone together.